<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176381</url>
  </required_header>
  <id_info>
    <org_study_id>mCRPC-PA</org_study_id>
    <nct_id>NCT03176381</nct_id>
  </id_info>
  <brief_title>Tissue Predictors of Abiraterone Benefit</brief_title>
  <official_title>Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Second Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Hebei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Second Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, prospective (study following participants forward in time),
      multi-center (study conducted in more than 1 center) study to identify the predictive factors
      that will effectively predict the response to abiraterone treatment in metastatic
      castration-resistant prostate cancer (mCRPC). The entire duration of study will be
      approximately 3 year. Participants will primarily be evaluated for achieving biochemical or
      radiological progression after receiving abiraterone treatment based on EAU 2017 practice
      guideline criteria. For this, we put our attentions on the FKBP5 (FK506 Binding Protein 5,
      Androgen-regulated gene), NTS (neurotensin, neuroendocrine differentiation can be induced by
      NTS) and YAP1 (yes-associated protein 1, a biomarker for cancer stem cell), which are
      selected from the data of gene-array for various subtypes of CRPC (unpublished data).
      Response to abiraterone treatment will also be predicted using other androgen-regulated genes
      like AKR1C3 and PCNA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is now accepted that castration-resistant prostate cancer (CRPC) is not really
      androgen-independent and continues to rely on androgen signaling. Abiraterone is an inhibitor
      of cytochrome P450 17A1 (CYP17A1) that impairs androgen-receptor signaling by depleting
      adrenal and intratumoral androgens. After studies showed improved survival with abiraterone,
      it was approved by the Food and Drug Administration for the treatment of metastatic
      castration-resistant prostate cancer (mCRPC).

      mCRPC is a syndrome other than a disease. The mechanisms of mCRPC contain aberrant activation
      of androgen signaling, abnormal transition between epithelial and mesenchymal and induction
      of neuroendocrine differentiation (NED). In addition, cellular heterogeneity represents an
      omnipresent feature in human tumors, which contain cells with diverse morphology, cytogenetic
      markers, growth kinetics, immunological characteristics, metastatic ability, and sensitivity
      to therapeutics.

      This is an observational, prospective (study following participants forward in time),
      multi-center (study conducted in more than 1 center) study to identify the predictive factors
      that will effectively predict the response to abiraterone treatment in metastatic
      castration-resistant prostate cancer (mCRPC). The entire duration of study will be
      approximately 3 year. Participants will primarily be evaluated for achieving biochemical or
      radiological progression after receiving abiraterone treatment based on EAU 2017 practice
      guideline criteria. For this, we put our attentions on the FKBP5 (FK506 Binding Protein 5,
      Androgen-regulated gene), NTS (neurotensin, neuroendocrine differentiation can be induced by
      NTS) and YAP1 (yes-associated protein 1, a biomarker for cancer stem cell), which are
      selected from the data of gene-array for various subtypes of CRPC. Response to abiraterone
      treatment will also be predicted using other androgen-regulated genes like AKR1C3 and PCNA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Anticipated">May 5, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 5, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PSA response rates</measure>
    <time_frame>2 YEARS</time_frame>
    <description>PSA response rates between FKBP5(protein)-positive and FKBP5(protein)-negative (including YAP1-positive and NTS-positive) patients; PSA response rates between patients with higher or lower expression of androgen-regulated genes (AKR1C3, FKB5, PCNA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA progression-free survival (pPFS)</measure>
    <time_frame>3 YEARS</time_frame>
    <description>pPFS between FKBP5-positive and FKBP5-negative (including YAP1-positive and NTS-positive) patients; pPFS between patients with higher or lower expression of androgen-regulated genes (AKR1C3, FKB5, PCNA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical or radiographic progression-free survival (cPFS)</measure>
    <time_frame>3 YEARS</time_frame>
    <description>cPFS between FKBP5-positive and FKBP5-negative (including YAP1-positive and NTS-positive) patients; cPFS between patients with higher or lower expression of androgen-regulated genes (AKR1C3, FKB5, PCNA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>3 YEARS</time_frame>
    <description>OS between FKBP5-positive and FKBP5-negative (including YAP1-positive and NTS-positive) patients; OS between patients with higher or lower expression of androgen-regulated genes (AKR1C3, FKB5, PCNA).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      mRNA panel with AKR1C3, FKB5 and PCNA would be tested in the tissue specimen.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants having indication and planning to receiving abiraterone treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants who have given consent form;

          2. Patients with a confirmed diagnosis of mCRPC according to EAU 2017 guideline;

          3. Serum testosterone must reach castration level: &lt;50 ng per deciliter;

          4. Participants with life expectancy of at least 6 months based on the Investigator's
             clinical judgment.

        Exclusion Criteria:

          1. Participants who are allergic to contrast medium;

          2. Patients were excluded if they planned to receive additional concurrent anticancer
             therapies;

          3. Patients doesn't sign an informed consent form.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rong Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Second Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimiao Zhu</last_name>
    <phone>+8613752436539</phone>
    <email>zhushimiao@tijmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical Unversity Second Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Han</last_name>
      <phone>+86 022 8832 8677</phone>
      <email>miyansuo@126.com</email>
    </contact>
    <investigator>
      <last_name>Yuanjie Niu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shimiao Zhu, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):479-81. doi: 10.1056/NEJMe1006300.</citation>
    <PMID>20818868</PMID>
  </reference>
  <reference>
    <citation>Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 2011 Sep 20;29(27):3651-8. doi: 10.1200/JCO.2011.35.2005. Epub 2011 Aug 22. Review.</citation>
    <PMID>21859989</PMID>
  </reference>
  <reference>
    <citation>O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004 Jun 14;90(12):2317-25.</citation>
    <PMID>15150570</PMID>
  </reference>
  <reference>
    <citation>Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896.</citation>
    <PMID>18645193</PMID>
  </reference>
  <reference>
    <citation>Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.</citation>
    <PMID>22894553</PMID>
  </reference>
  <reference>
    <citation>de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.</citation>
    <PMID>21612468</PMID>
  </reference>
  <reference>
    <citation>Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.</citation>
    <PMID>23228172</PMID>
  </reference>
  <reference>
    <citation>Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012 Mar;22(3):457-72. doi: 10.1038/cr.2012.13. Epub 2012 Jan 17. Review.</citation>
    <PMID>22357481</PMID>
  </reference>
  <reference>
    <citation>Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011 Jun 14;19(6):792-804. doi: 10.1016/j.ccr.2011.05.006. Epub 2011 May 27.</citation>
    <PMID>21620777</PMID>
  </reference>
  <reference>
    <citation>Swift SL, Burns JE, Maitland NJ. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res. 2010 Jan 1;70(1):347-56. doi: 10.1158/0008-5472.CAN-09-1252.</citation>
    <PMID>20048080</PMID>
  </reference>
  <reference>
    <citation>Valerie NC, Casarez EV, Dasilva JO, Dunlap-Brown ME, Parsons SJ, Amorino GP, Dziegielewski J. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Cancer Res. 2011 Nov 1;71(21):6817-26. doi: 10.1158/0008-5472.CAN-11-1646. Epub 2011 Sep 8.</citation>
    <PMID>21903767</PMID>
  </reference>
  <reference>
    <citation>Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, Stylianou N, Sweeney K, Soekmadji C, Jovanovic L, Nelson CC, Zoubeidi A, Butler LM, Goodall GJ, Hollier BG, Gregory PA, Tilley WD. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2017 Jan 5;36(1):24-34. doi: 10.1038/onc.2016.185. Epub 2016 Jun 6.</citation>
    <PMID>27270433</PMID>
  </reference>
  <reference>
    <citation>Thoma C. Prostate cancer: Targetable YAP1-AR interaction key to disease progression. Nat Rev Urol. 2015 Nov;12(11):596. doi: 10.1038/nrurol.2015.240. Epub 2015 Sep 22.</citation>
    <PMID>26390969</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Abiraterone Acetate</keyword>
  <keyword>FK506 binding protein 5</keyword>
  <keyword>Neurotensin</keyword>
  <keyword>yes-associated protein 1</keyword>
  <keyword>AKR1C3 protein</keyword>
  <keyword>Proliferating Cell Nuclear Antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD can be got by contacting researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

